Mesalazina Sandoz

Mesalazine, the active ingredient in Mesalazina Sandoz, is a 5-aminosalicylic acid (5-ASA) presented as an oral formulation for systemic use. It is employed to treat inflammatory bowel conditions such as ulcerative colitis and Crohn's disease with colonic involvement. GNH USA supplies Mesalazina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazina Sandoz belongs to the 5‑ASA class and is used to manage inflammatory bowel disease. - Ulcerative colitis: reduces mucosal inflammation and helps achieve and maintain remission. - Crohn's disease (colonic involvement): controls intestinal inflammation and alleviates symptoms. - Inflammatory bowel disease maintenance: supports long‑term disease control and decreases relapse frequency.

Mesalazina Sandoz may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: usually transient. - Abdominal pain or cramping: may occur during the first weeks. - Diarrhoea or loose stools: often mild. - Flatulence: increased intestinal gas. - Rash or mild skin irritation.

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Renal impairment or interstitial nephritis. - Blood dyscrasias: leukopenia, thrombocytopenia, or anemia. - Pancreatitis: acute abdominal pain with elevated enzymes. - Anaphylaxis or severe allergic reactions.

Before initiating therapy, clinicians should consider several safety measures. - Renal function: monitor serum creatinine and eGFR regularly. - Hepatic function: assess liver enzymes at baseline and periodically. - Hematology: perform complete blood counts to detect leukopenia or thrombocytopenia. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Concomitant NSAIDs: avoid or use with caution due to increased renal toxicity. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mesalazina Sandoz can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Azathioprine or 6‑mercaptopurine: increased risk of bone‑marrow suppression. - Sulfasalazine: additive gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened potential for renal impairment. - Warfarin: possible alteration of INR, requiring closer monitoring. - Oral contraceptives: may reduce contraceptive efficacy, advise additional barrier methods.